SIRT2 is associated with prognosis, ferroptosis susceptibility, and immune infiltration in lung adenocarcinoma
Wei Zhang, Li-sha Ren, Huan Bai, Ying-ying Mu, Yue Qian, Hongyu Chen · 2026
Read SIRT2 is associated with prognosis, ferroptosis susceptibility, and immune infiltration in lung adenocarcinoma by Wei Zhang, Li-sha Ren, Huan Bai, Ying-ying Mu, Yue Qian, Hongyu Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13612300.txt.
Description
Wei Zhang and co-authors probe a longevity-linked enzyme that runs low in lung adenocarcinoma and tracks with worse fate. Their 2026 study mines public tumor datasets for the enzyme SIRT2. It is the fastest-growing lung cancer subtype, and late cases still lack good options.
Tumors showed far less of the enzyme than healthy tissue. Low levels tracked with higher stage and shorter survival on every clock. Pathway maps tied it to core growth signals, to an iron-driven cell death route, and to immune cell mix inside tumors. Docking screens hunted drugs that might engage it. Dish tests on a lung cancer cell line backed the data picture. The authors name the enzyme as marker and target lead.
Catalog record
| CREATOR | Wei Zhang, Li-sha Ren, Huan Bai, Ying-ying Mu, Yue Qian, Hongyu Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |